Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
about
Targeted immunotherapy for pediatric solid tumorsEmerging importance of ALK in neuroblastomaTargeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signalingChemical genetic strategy for targeting protein kinases based on covalent complementarityMechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine ReleaseUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsCrizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancerInterplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer TherapyTransgenic plants as low-cost platform for chemotherapeutic drugs screeningCooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition.The potential for crizotinib in non-small cell lung cancer: a perspective reviewEpidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapiesForetinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphomaHepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinomaRas effector mutant expression suggest a negative regulator inhibits lung tumor formation.Detecting and targetting oncogenic fusion proteins in the genomic era.Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.Mechanisms and Therapy for Cancer Metastasis to the Brain.A Computational Approach for Prioritizing Selection of Therapies Targeting Drug Resistant Variation in Anaplastic Lymphoma Kinase.Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.
P2860
Q26747703-B16F0D33-653C-4FAC-8C5F-94E0B359DF5EQ26858819-EEE43FBF-F866-4B0A-882D-AA8B66548EE5Q27011423-513753F6-04E8-42D4-A4B2-376FA6D19A9FQ27671824-645B3254-8F65-4D77-8C66-1C7422BA1CCBQ27851710-6097CBB8-84BD-4BFA-AEB8-9A482A6F736BQ28263364-8A3D3897-684B-4DBD-9EB3-71194E7B2DF1Q28546245-B0D4556B-6DDB-4A80-AE19-47D8E16E47C1Q34619273-5838B9FA-0252-4AF6-8B17-219547242842Q34971882-A4426B47-CDAC-424C-940E-69C01B1D0C3AQ35016736-22F0D22F-4BF8-41C5-AE54-BAC865108547Q35180335-FDE99C22-DF4D-4F4D-BE29-0468890029AEQ35534514-5DA849E5-8902-4272-B50B-67F5849FE821Q35549063-FAB89198-6B10-46FD-AC7A-97C6EC557C68Q36020888-EF8768A1-AC42-4E20-BAA6-50E24EEAB6BFQ36646078-3ACCBAFA-8A33-46FD-A141-54A22557ACEEQ36739725-69882030-8B55-40FD-B0B1-7FB2D7ED32D1Q36868642-B06D60DE-C08D-4EC7-88B6-AA35A380811EQ37525082-32E2B944-0FAC-4532-89BD-CDCB41765E6AQ38336067-E5E0465D-CB9D-4D31-A553-FD0047D8223BQ38829675-AA30F365-F84E-403F-9F05-D7971B53B0CCQ38941704-09DB1802-FB82-4F7E-9FD8-1D6DFBE2180DQ39428273-1CCE4606-902E-4096-A898-0C8A286C3145Q40999620-36A0F2A9-750A-44C6-B540-52AECF7F5AD2Q41461306-F99D79E7-7EDC-4D3B-959C-EC37971811DDQ41712860-425768B6-2075-4AFE-B2E7-EC578C618031Q41994295-B796A3FB-62F8-4014-A981-0EBA569298E1Q47121196-ADAFA042-2311-403F-A4C6-ADB41BA57CFFQ49820833-0A751DD6-D0F7-4EDB-977E-7C007F999823Q50985091-44FD60F3-3362-477E-8AE3-33EBA3C62A6BQ54950354-C0A8B132-F0DB-4DFE-8F6B-1F78DF7064F0Q54976582-1C7B5487-DA97-449A-8AFD-1A98FB756C4AQ54977430-5AD188A0-B45F-4D0B-B732-D71F085DC7EB
P2860
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Crizotinib, a small-molecule d ...... ALK receptor tyrosine kinases.
@en
Crizotinib, a small-molecule d ...... ALK receptor tyrosine kinases.
@nl
type
label
Crizotinib, a small-molecule d ...... ALK receptor tyrosine kinases.
@en
Crizotinib, a small-molecule d ...... ALK receptor tyrosine kinases.
@nl
prefLabel
Crizotinib, a small-molecule d ...... ALK receptor tyrosine kinases.
@en
Crizotinib, a small-molecule d ...... ALK receptor tyrosine kinases.
@nl
P1476
Crizotinib, a small-molecule d ...... ALK receptor tyrosine kinases
@en
P2093
Geoffrey I Shapiro
Scott J Rodig
P304
P577
2010-12-01T00:00:00Z